{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:49:43Z","timestamp":1793692183069,"version":"4.5.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00702-020-02257-0","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T22:02:30Z","timestamp":1602280950000},"page":"1599-1606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of effectiveness of trihexyphenidyl and levodopa on motor symptoms in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"127","author":[{"given":"Lulup Kumar","family":"Sahoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram Venkappayya","family":"Holla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabh","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitish","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-2377","authenticated-orcid":false,"given":"Pramod Kumar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"2257_CR1","first-page":"802","volume":"87","author":"A Barbeau","year":"1962","unstructured":"Barbeau A (1962) The pathogenesis of Parkinson\u2019s disease: a new hypothesis. Can Med Assoc J 87:802","journal-title":"Can Med Assoc J"},{"key":"2257_CR2","first-page":"39","volume":"2","author":"DR Brocks","year":"1999","unstructured":"Brocks DR (1999) Anticholinergic drugs used in Parkinson\u2019s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci 2:39\u201346","journal-title":"J Pharm Pharm Sci"},{"key":"2257_CR3","first-page":"131","volume":"40","author":"C Clough","year":"1984","unstructured":"Clough C, Bergmann K, Yahr M (1984) Cholinergic and dopaminergic mechanisms in Parkinson\u2019s disease after long-term L-DOPA administration. Adv Neurol 40:131\u2013140","journal-title":"Adv Neurol"},{"key":"2257_CR4","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/nn1700","volume":"9","author":"J Ding","year":"2006","unstructured":"Ding J et al (2006) RGS4-dependent attenuation of M4 autoreceptor function in striatal cholinergic interneurons following dopamine depletion. Nat Neurosci 9:832\u2013842. https:\/\/doi.org\/10.1038\/nn1700","journal-title":"Nat Neurosci"},{"key":"2257_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"75","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Bloem BR (2018) The Parkinson pandemic\u2014a call to action. JAMA Neurol 75:9\u201310","journal-title":"JAMA Neurol"},{"key":"2257_CR6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER et al (2018) Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study. Lancet Neurol 17:939\u2013953","journal-title":"Lancet Neurol"},{"key":"2257_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1001\/archneur.1967.00470260014002","volume":"17","author":"RC Duvoisin","year":"1967","unstructured":"Duvoisin RC (1967) Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 17:124\u2013136. https:\/\/doi.org\/10.1001\/archneur.1967.00470260014002","journal-title":"Arch Neurol"},{"key":"2257_CR8","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH et al (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord 33:1248\u20131266. https:\/\/doi.org\/10.1002\/mds.27372","journal-title":"Mov Disord"},{"key":"2257_CR9","first-page":"19","volume":"45","author":"O Hornykiewicz","year":"1987","unstructured":"Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson\u2019s disease. Adv Neurol 45:19\u201334","journal-title":"Adv Neurol"},{"key":"2257_CR10","doi-asserted-by":"crossref","unstructured":"Katzenschlager R, Sampaio C, Costa J, Lees A (2002) Anticholinergics for symptomatic management of Parkinson s disease. Cochrane Database Syst Rev","DOI":"10.1002\/14651858.CD003735"},{"key":"2257_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1001\/archneur.1986.00520020020009","volume":"43","author":"WC Koller","year":"1986","unstructured":"Koller WC (1986) Pharmacologic treatment of parkinsonian tremor. Arch Neurol 43:126\u2013127","journal-title":"Arch Neurol"},{"key":"2257_CR12","unstructured":"Koller WC, Silver DE, Lieberman A (1994) An algorithm for the management of Parkinson\u2019s disease. Neurology"},{"key":"2257_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1755-5949.2010.00142.x","volume":"16","author":"DB Lester","year":"2010","unstructured":"Lester DB, Rogers TD, Blaha CD (2010) Acetylcholine\u2013dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:137\u2013162","journal-title":"CNS Neurosci Ther"},{"key":"2257_CR14","first-page":"167","volume":"66","author":"S-Y Lim","year":"2009","unstructured":"Lim S-Y, Fox SH, Lang AE (2009) Overview of the extranigral aspects of Parkinson disease. Arch Neurol 66:167\u2013172","journal-title":"Arch Neurol"},{"key":"2257_CR15","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/jnnp.57.6.672","volume":"57","author":"CD Marsden","year":"1994","unstructured":"Marsden CD (1994) Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 57:672\u2013681. https:\/\/doi.org\/10.1136\/jnnp.57.6.672","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2257_CR16","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1212\/wnl.24.10.912","volume":"24","author":"WE Martin","year":"1974","unstructured":"Martin WE, Loewenson RB, Resch JA, Baker AB (1974) A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson\u2019s disease. Neurology 24:912\u2013919. https:\/\/doi.org\/10.1212\/wnl.24.10.912","journal-title":"Neurology"},{"key":"2257_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0022-510x(94)90028-0","volume":"125","author":"T Mitsui","year":"1994","unstructured":"Mitsui T, Kawai H, Sakoda S, Miyata M, Saito S (1994) Hereditary parkinsonism with multiple system degeneration: beneficial effect of anticholinergics, but not of levodopa. J Neurol Sci 125:153\u2013157. https:\/\/doi.org\/10.1016\/0022-510x(94)90028-0","journal-title":"J Neurol Sci"},{"key":"2257_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0014-2999(87)90123-3","volume":"142","author":"JW Olney","year":"1987","unstructured":"Olney JW, Price MT, Labruyere J, Shahid Salles K, Frierdich G (1987) Anti-parkinsonia agents are phencyclidine agonists and N-methyl-aspartate antagonists. Eur J Pharmacol 142:319\u2013320","journal-title":"Eur J Pharmacol"},{"key":"2257_CR19","doi-asserted-by":"publisher","first-page":"9237181","DOI":"10.1155\/2019\/9237181","volume":"2019","author":"K Orayj","year":"2019","unstructured":"Orayj K, Lane E (2019) Patterns and determinants of prescribing for Parkinson\u2019s disease: a systematic literature review. Parkinsons Dis 2019:9237181. https:\/\/doi.org\/10.1155\/2019\/9237181","journal-title":"Parkinsons Dis"},{"key":"2257_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/jnnp.37.4.422","volume":"37","author":"J Parkes","year":"1974","unstructured":"Parkes J, Baxter R, Marsden C, Rees J (1974) Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 37:422\u2013426","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2257_CR21","unstructured":"Roberson ED (2017) Treatment of Central Nervous System Degenerative Disorders. In: Brunton LL, Hilal-Dandan R, Knollmann BC (eds) Goodman & Gilman\u2019s: The Pharmacological Basis of Therapeutics, 13e. McGraw-Hill Education, New York, NY"},{"key":"2257_CR22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1017\/cjn.2017.208","volume":"44","author":"P Surathi","year":"2017","unstructured":"Surathi P, Kamble N, Bhalsing KS, Yadav R, Pal PK (2017) Prescribing pattern for Parkinson\u2019s disease in Indian Community before referral to tertiary center. Can J Neurol Sci 44:705\u2013710. https:\/\/doi.org\/10.1017\/cjn.2017.208","journal-title":"Can J Neurol Sci"},{"key":"2257_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/jnnp.72.1.111","volume":"72","author":"H Yamada","year":"2002","unstructured":"Yamada H, Momose T, Okada M, Kuroiwa Y (2002) Anticholinergic drugs: response of parkinsonism not responsive to levodopa. J Neurol Neurosurg Psychiatry 72:111\u2013113. https:\/\/doi.org\/10.1136\/jnnp.72.1.111","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-020-02257-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-020-02257-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-020-02257-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T07:22:33Z","timestamp":1633850553000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-020-02257-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2257"],"URL":"https:\/\/doi.org\/10.1007\/s00702-020-02257-0","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"assertion":[{"value":"4 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None of the authors have any financial disclosure to make or have any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}